KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments.

Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc., as the company’s wholly-owned research division, allows the company to foster value creation through its clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.

As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Name KetamineOne Capital
Symbol MEDI
Website https://www.ketamine.one/
Twitter https://twitter.com/ketamineone